目的 研究卡馬西平聯(lián)合鹽酸洛美利嗪膠囊治療偏頭痛的臨床治療效果。方法 選擇2012年2月-2016年12月在新疆醫(yī)科大學(xué)第六附屬醫(yī)院進(jìn)行診治的偏頭痛患者70例，隨機(jī)分為觀察組與對(duì)照組，每組各35例。對(duì)照組患者于早晚飯后口服鹽酸洛美利嗪膠囊5 mg，每天2次，觀察組在此基礎(chǔ)上于餐后聯(lián)合口服卡馬西平，初始劑量為每次0.1 g，每天2次，第2天后每隔1天增加0.1~0.2 g，待疼痛緩解后，采用維持劑量0.4~0.8 g/d進(jìn)行治療，兩組均治療3個(gè)月。比較兩組的臨床治療效果，觀察兩組治療前后的24 h內(nèi)頭痛緩解維持時(shí)間和頭痛發(fā)作頻率，采用VAS對(duì)患者疼痛程度進(jìn)行評(píng)估，并隨訪1個(gè)月觀察患者的復(fù)發(fā)情況。結(jié)果 觀察組有效率為94.29%（33/35），明顯高于對(duì)照組的77.14%（27/35），差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。兩組治療后的24 h內(nèi)頭痛緩解維持時(shí)間均明顯增加（P<0.05），VAS評(píng)分以及頭痛發(fā)作頻率均明顯降低（P<0.05）；與對(duì)照組相比，觀察組上述觀察指標(biāo)改善程度較好，組間差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。經(jīng)過1個(gè)月的隨訪發(fā)現(xiàn)，對(duì)照組復(fù)發(fā)4例，觀察組復(fù)發(fā)1例，觀察組的復(fù)發(fā)率為2.86%（1/35），明顯低于對(duì)照組的11.43%（4/35），差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。觀察組的不良反應(yīng)發(fā)生率為17.14%（6/35），與對(duì)照組的11.43%（4/35）相比無明顯差異。結(jié)論 卡馬西平聯(lián)合鹽酸洛美利嗪膠囊對(duì)偏頭痛具有顯著的臨床效果，可以有效降低頭痛發(fā)作頻率，緩解頭痛程度，縮短發(fā)作時(shí)間，且復(fù)發(fā)率較低，安全性高，值得應(yīng)用推廣。

Objective To investigate the clinical effect oflomerizine hydrochloride capsules combined with carbamazepine in the treatment of migraine.Methods Selected 70 cases of patients with migraine who were treated in our hospital from February 2012 to December 2016, divided into two groups randomly, 35 cases in observation group, 35cases in control group. Patients in the control group were treated with Lomerizine Hydrochloride Capsules 5 mg orally 2 times a day after morning and evening. The observation group in combination with oral carbamazepine, the initial measurement for 0.1 g each time, 2 times a day, second days every 1 days increased 0.1-0.2 g, pain relief to be maintained by measurement of 0.4-0.8 g/d treatment. The clinical treatment effects were compared between the two groups, two groups were observed before and after treatment within 24 h headache remission duration and frequency of headache, to evaluate the degree of pain in patients with VAS, and followed up for 1months to observe the recurrence rate of patients.Results After treatment, the effective rate of the observation group was 94.29% (33/35), significantly higher than that of the control group 77.14% (27/35) (P< 0.05); within 24 h after treatment, headache relief, duration of maintenance were significantly increased (P< 0.05), and VAS scores and frequency of headache attacks were significantly lower (P< 0.05), compared with the control group, the observation group improved the above indexes better (P< 0.05); after 1 months of follow-up, 4 cases were found in the control group and 1 cases in the observation group. The recurrence rate of the observation group was 2.86% (1/35), which was significantly lower than that of the control group 11.43% (4/35) (P< 0.05);the incidence of adverse reactions in the observation group was 17.14% (6/35), has no significant difference with 11.43% (4/35) in the control group.Conclusion Lomerizine Hydrochloride Capsules combined with carbamazepine has significant clinical effect on migraine, which can effectively reduce the frequency of headache, alleviate the headache, shorten the onset time, and have a low recurrence rate and high safety.